Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143891 · ClinicalTrials.gov registry record · Phase 3
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
A Phase 3 study of Chronic Graft Versus Host Disease, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT06143891: Active Phase 3 study of Chronic Graft Versus Host Disease, sponsored by Sanofi.
NCT06143891 is a Phase 3 study of Chronic Graft Versus Host Disease that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 260 participants, above the 108-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (141% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06143891, a Phase 3 study of Chronic Graft Versus Host Disease, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.
Primary Outcome
From the date of randomization to the date of any predefined event, whichever occurs first
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Belumosudil
- DRUG Prednisone
- DRUG Prednisolone
Study Locations (20)
California
- City of Hope National Medical Center- Site Number : 8400001 - Duarte
- University of California San Francisco - Parnassus Heights- Site Number : 8400035 - San Francisco
North Carolina
- UNC Children's Hospital- Site Number : 8400025 - Chapel Hill
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem - Medical Center Boulevard- Site Number : 8400007 - Winston-Salem
Ohio
- Oncology Hematology Care - Kenwood- Site Number : 8400030 - Cincinnati
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute- Site Number : 8400026 - Columbus
Texas
- St. David's South Austin Medical Center- Site Number : 8400002 - Austin
- Texas Oncology - Dallas - Worth Street- Site Number : 8400010 - Dallas
Arkansas
- University of Arkansas for Medical Sciences-Site Number : 8400019 - Little Rock
Florida
- AdventHealth Orlando- Site Number : 8400023 - Orlando
Georgia
- The Hope Clinic of Emory University- Site Number : 8400020 - Decatur
Illinois
- Northwestern University- Site Number : 8400017 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2028-09-29 |
| Phase | Phase 3 |
What the registry record for NCT06143891 still lists
NCT06143891 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (141% higher).
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06143891 names 20 study sites across 16 states, led by California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT06143891 about?
NCT06143891 is a clinical study titled "A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.". This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of ...
What is the current status of trial NCT06143891?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2024-01-23. Estimated completion is 2028-09-29.
What conditions does trial NCT06143891 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT06143891?
The interventions under investigation include: Placebo (DRUG), Belumosudil (DRUG), Prednisone (DRUG), Prednisolone (DRUG).
Who is sponsoring clinical trial NCT06143891?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143891 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06143891's enrollment target sits among peer trials
260 4th of 30 higher than 27 of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
RECRUITING · Phase 3
-
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
COMPLETED · Phase 3
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
RECRUITING
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI